Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Assembly Biosciences (ASMB) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Assembly Biosciences (ASMB) over the last 9 years, with Q3 2025 value amounting to -$9.2 million.

  • Assembly Biosciences' Net Income towards Common Stockholders rose 433.79% to -$9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.5 million, marking a year-over-year increase of 553.13%. This contributed to the annual value of -$40.2 million for FY2024, which is 3438.13% up from last year.
  • According to the latest figures from Q3 2025, Assembly Biosciences' Net Income towards Common Stockholders is -$9.2 million, which was up 433.79% from -$10.2 million recorded in Q2 2025.
  • Assembly Biosciences' 5-year Net Income towards Common Stockholders high stood at -$8.8 million for Q1 2025, and its period low was -$62.8 million during Q4 2021.
  • Over the past 4 years, Assembly Biosciences' median Net Income towards Common Stockholders value was -$11.2 million (recorded in 2024), while the average stood at -$17.5 million.
  • As far as peak fluctuations go, Assembly Biosciences' Net Income towards Common Stockholders crashed by 46145.12% in 2021, and later skyrocketed by 5210.03% in 2024.
  • Quarter analysis of 4 years shows Assembly Biosciences' Net Income towards Common Stockholders stood at -$62.8 million in 2021, then skyrocketed by 82.54% to -$11.0 million in 2023, then grew by 5.72% to -$10.3 million in 2024, then increased by 11.02% to -$9.2 million in 2025.
  • Its Net Income towards Common Stockholders was -$9.2 million in Q3 2025, compared to -$10.2 million in Q2 2025 and -$8.8 million in Q1 2025.